nmCRPC: Clinical Trial Data on AR Inhibitors

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Related Videos
Jeffery Zonder, MD
Expert on lung cancer
Expert on lung cancer
David R. Wise, MD, PhD
Expert on DLBCL
Experts on prostate cancer
Experts on prostate cancer
Andrew Kin, MD
Related Content